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1. Introduction 
1.1. History, definition and classification 
Life and death are essential parts of the natural cycle of all multicellular organisms. In 
metazoans, somatic cells divide normally during the process known as mitosis. Cell 
proliferation is tightly controlled, according to the organism needs. An increase in the 
number of cells takes place during growth and when one of these cells finishes its 
physiological function or detects DNA or cell damage, it undergoes a physiological process 
known as apoptosis that induces its own death. In humans about a hundred thousand cells 
are formed every second through mitosis, while a similar number is destroyed by apoptosis 
[1]. This dynamic balance between proliferation and cell death is known as homeostasis. If 
altered, different pathologic processes such as carcinogenesis can take place. Besides its role 
in embryonic development, homeostasis maintenance and aging, apoptosis is also a defence 
mechanism by which infected, injured or mutated cells as a result of irradiation or 
chemotherapeutic drugs are eliminated. This type of cell death involves the activation of an 
evolutionary conserved and tightly regulated intracellular machinery that requires energy 
consumption [2]. An important feature of apoptosis is that the cell is eliminated without 
triggering an immune response, avoiding thus tissue damage [3]. 
The term apoptosis to describe cell death was introduced by Kerr and colleagues in 1972 [4], 
from the Greek term “appo-teo-sis” which means “falling off” (as in leaves from a tree or 
petals from a flower). Apoptosis has been used as a synonym of programmed cell death and 
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refers to a suicidal type of death. However, as more mechanisms of programmed cell death 
are being elucidated, the Nomenclature Committee on Cell Death (NCCD) recommends 
caution when using the term apoptosis [5]. Historically, the classical methods to define cell 
death rely on morphological criteria. Thus, apoptosis was termed programmed cell death 
type I, autophagy named as programmed cell death type II and necrosis as a type of death 
lacking characteristics of both type I and type II. As more biochemical methods become 
available over the last decades, a more definite and concise classification of types of cell 
death has become necessary. Therefore, cell death types can be classified according to 
morphological appearance, biochemical features, functional criteria or immunological 
aspects. In the following figure (Figure 1) the classification of different types of cell death, in 
accordance with to the NCCD are described: 
 
Figure 1. Classification of different types of cell death according to the NCCD (modified from Galluzzi 
et al. 2012) 
It is important to mention that a single stimulus can trigger more than one mechanism of 
cell death simultaneously within a cell. However, only the most efficacious mechanism will 
be prevalent. 
2. Apoptosis 
2.1. Morphological and biochemical features 
Morphological features that share both caspase-dependent and independent apoptotic 
pathways are: a) loss of plasma membrane symmetry and loss of cell-to-cell contact and cell 
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round-up, b) chromatin condensation (picnosis) and fragmentation and nuclear breakdown, 
c) overall cell shrinkage and cytoskeleton alterations although the majority of the cell 
organelles remain intact, d) membrane blebbing and formation of the membrane-enclosed 
particles called apoptotic bodies that contain nuclear or cytoplasmic material and will be 
engulfed by phagocytes or neighbouring cells [6]. 
Because apoptotic cells are eaten so quickly, there are few dead cells left on tissue sections. 
This is the reason why apoptosis was neglected by pathologists for a long time, even though 
apoptosis is the main mechanism for discarding of harmful or unwanted cells in 
multicellular organisms. 
Along with the morphological transformation described, there are several biochemical 
alterations that take place. For instance, activation of endonucleases, some of them 
dependent on Ca2+ and Mg2+ channels, that cleaves genomic DNA. In the apoptotic 
process, this event gives rise to internucleosomal DNA double-strand breaks with 
fragments of multiples of 180 bp, resulting in the typical pattern of DNA ladder that can be 
detected by electrophoresis on agarose gels. Other changes include loss of the inner 
mitochondrial transmembrane potential [7] and exposure of the phospholipid 
phosphatidylserine to the outer cell membrane, which allows phagocytes to detect and 
engulf these apoptotic cells [8]. 
 
Figure 2. Features of Apoptosis, Oncosis and Necrosis (taken from Hail et al., 2006) 
The most distinguishable feature of apoptosis is the formation of apoptotic bodies. On the 
other hand, oncosis is characterized by cytoplasmic swelling, dilation of organelles and 
vacuolization and plasma membrane blebbing. The cell will finally die by cytolysis, which is 
a typical hallmark of necrosis [9]. Apoptotic cells can also lose their plasma membrane and 
eventually undergo a secondary necrosis. However, this phenomenon has only been 
observed in vitro. According to Majno and Joris, necrosis is not a type of cell death, but 
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rather, it refers to changes subsequent to any type of death. They prefer to use the term 
oncosis to describe a nonprogrammed or accidental type of cell death characterized by 
swelling [10]. Moreover, a new modality of cell death has recently emerged, termed 
necroptosis to indicate a regulated form of necrosis [11]. 
Apoptosis can be divided into three stages: initiation, integration/decision and 
execution/degradation [12]. The initiation phase mainly depends upon cell type and 
apoptotic stimulus. The integration/decision phase consists of the activation of proteases, 
nucleases and other effector molecules. The execution/degradation phase involves 
morphological and biochemical changes that are common to all apoptotic mechanisms, 
regardless of the stimulus that initiated the process. The classical apoptosis is defined as a 
type of programmed cell death characterized by the activation of zymogens known as 
caspases, which are cystein-dependent aspartate-directed proteases. Both caspase-
dependent and caspase-independent cell death mechanisms share multiple characteristics, 
such as mitochondrial membrane permeabilization (MMP), DNA fragmentation, etc. Hence, 
(MMP) can commit cells to die even in the absence of caspase activation, by releasing factors 
such as apoptosis inducing-factor (AIF) or endonuclease G (endo G). 
3. Caspases: Executioners of the apoptotic process 
Caspases are the effector molecules of apoptosis in mammals. They were first discovered 
mediating programmed cell death during development in the nematode Caenorhabditis 
elegans [13]. The caspase family is characterized by their specificity for cleaving substrates 
after aspartic acid residues and for containing cystein in their active centre [14]. There are 
about fourteen caspases that used to be classified into two families: one involved in 
inflammation processes and the other taking part in apoptosis. However, some of the non-
apoptotic caspases have some apoptotic roles, and conversely, some non-apoptotic caspases 
can induce pyroptosis [15]. They are synthesized as inactive precursors or zymogens (pro-
caspases) that need to be proteolytically processed to become active. Once a caspase is 
activated, it can cleave another caspase creating thus an expansive hierarchical activating 
cascade that serves to amplify the apoptotic signal. Caspase activation is a complex and 
tightly regulated process. Within the apoptotic group, there are two types of caspases: 
upstream initiator or apical caspases and downstream effector or executioner caspases. The 
initiator group consists of caspases -2, -8, -9 and -10 and the effector group consists of -3, -6 
and -7 caspases. Apical but not executioner caspases have long prodomains. Caspase-9 is 
considered the initiator of the mitochondrial pathway and caspase-8 is regarded as the 
originator of the dead receptor-mediated apoptotic pathway. Effector caspases carry out 
apoptotic programmes through direct processing of a variety of cellular substrates. The 
proteolytic cleavage of such substrates brings about a whole plethora of effects within the 
cell: disassembling of cytoskeleton, cytoplasm scaffolding, nuclear fragmentation as a 
consequence of laminin degradation, activation of endonucleases that cleave chromatin, 
inactivation of DNA damage repair proteins (PARP1, Rad9, etc.), phagocyte signalling, loss 
of cell-to-cell contact, etc. [16-18] 
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Substrate Funtion
PARP, DSBs, Rad51 and Rad9, DNA-
PKCs and ATM 
DNA damage repair  
C1, C2 and U170 mRNA processing 
Actin, Gas2, FAK, PAK2, Fodrin and 
Gelsolin 
Cellular structure 
PKC and Akt Apoptosis and cell cycle 
Phosphatase 2A, Raf1 and Rb Cell cycle 
Bid, Bcl-2, Bcl-xL and XIAP Apoptosis regulation 
Pro-IL-1β Cytokine 
D4-GDP Inhibitor Rho GTPases regulator 
Laminin A/C and B and NuMA Nuclear shape maintenance 
ACINUS Regulation of chromatin condensation 
ICAD DNA fragmentation 
Huntingtin Huntington disease 
SREBP-1 and SREBP-2 Sterol regulatory element binding proteins 
MDM2 Transcription factor 
Table 1. Proteins substrates of caspases (Blank and Shiloh 2007; Cohen et al 1997) 
Caspase activity can be regulated both in a positive and in a negative manner. Negative 
caspase regulators are called Inhibitors of Apoptosis Proteins (IAPs) that bind to the 
catalytic site of caspases neutralizing its activity [19], or targeting them to degradation by 
ubiquinitation [20,21]. Some examples of IAPs are: XIAP, c-IAP1, c-IAP2, NAIP and 
survivin. On the other hand, Smac/DIABLO and Omi/HtrA2 act as positive regulators by 
inactivating IAPs [22]. 
4. Extrinsic and intrinsic apoptotic pathways 
There are at least two main well characterized apoptotic routes: the death receptor or 
extrinsic pathway and the mitochondrial or intrinsic pathway. The extrinsic pathway plays a 
major role in tissue homeostasis and responds to external cues, coming especially from the 
immune system, whereas the intrinsic pathway is triggered as a response to various internal 
insults such as DNA damage, cytosolic calcium overload, starvation, oxidative stress, 
radiation, cytotoxic agents, etc., and involves mitochondrial destabilization [23,24]. 
The death receptor pathway is initiated by extracellular stimuli that are recognized by a 
subgroup of the tumour necrosis factor receptor (TNF-R) family named dead receptors 
(Fas/CD95/APO-1, TNFR1, TRAIL R1/DR4 and TRAIL R2/DR5). Upon binding of their 
ligands (FAS, TNFα and TRAIL) these receptors become activated and interact via their 
death domain with the protein motif Fas-associated death domain (FADD) in adapter 
proteins, forming the Death inducing signalling complex (DISC), which binds to the 
prodomain of the initiator caspase-8 [25]. Thus, caspase-8 is activated by dimerization, 
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which leads to autocatalyisis and consequently activation of executioner caspases -3, -6 and -
7 [26].  
The intrinsic mitochondrial pathway is characterized by the action of B-cell lymphoma (Bcl-
2) proteins. This family consists of proapoptotic and antiapoptotic proteins. The 
proapoptotic members promote mitochondrial outer membrane permeabilization (MOMP) 
and the antiapoptotic members counteract this action, so that the balance between these two 
groups of proteins determines the final outcome [27,28]. If the balance is in favour of the 
proapoptotic members, the outer mitochondrial membrane is permeabilized through pore 
formation and cytchrome c and other proteins such as Smac/DIABLO and Omi/HtrA2 are 
released to the cytosol. Then, cytochrome c binds to the adaptor protein Apaf-1 and dATP, 
forming the apoptosome, a catalytic complex that activates caspase-9 which in turn activates 
the executioner caspases. 
The extrinsic and intrinsic pathways are interconnected through Bid. In some cases, when 
DISC formation is low, caspase-8 activation can induce MOMP through Bid cleavage, which 
translocates to the mitochondria and induces cytchrome c release, apoptosome formation 
and engagement of the caspase cascade [29]. 
 
Figure 3. The extrinsic and intrinsic apoptotic pathways. 
5. Death receptors 
Death receptors belong to the TNF-R superfamily of receptors. They participate in 
proliferation, differentiation, immune response, gene expression, survival and cell death. In 
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fact, TNF-R1 and Fas (CD95/APO-1) are involved in apoptotic processes [30]. Death 
receptors are stimulated by death ligands: TNF; Fas ligand (FasL) and TNF-related 
apoptosis-inducing ligand (TRAIL). Death receptors contain an intracellular globular 
interaction domain called death domain (DD). Upon ligand binding, death receptors 
aggregate forming trimers. As a consequence of this aggregation, they recruit adaptors such 
as FADD, which interacts with caspase-8 by virtue of its death effector domain (DED), 
forming the multi-protein complex known as DISC. However, in some instances, death 
receptors can oligomerize in the abscence of ligand binding. For example, they can be 
activated by UV radiation [31]. Fas and TNF-R1 can also recruit RIP (receptor-interacting 
protein) -associated Ich-1/CED homologous [ICE (interleukin-1β-converting enzyme)/CED-3 
(cell-death determining 3) homologue 1] protein with death domain (RAIDD) which 
activates caspase-2 through a caspase activation and recruitment domain (CARD). In 
addition, death receptors can participate in caspase-independent mechanisms. For instance, 
TNF-R1 can activate Extracellular signal-regulated kinase 2 (Erk2) through the mitogen-
activated kinase activating death domain (MADD) protein [32]. Fas can bind Death-domain 
associated protein (Daxx) and activate c-Jun amino-terminal kinase (JNK) [33]. TNF-receptor 
associated death domain (TRADD) and RIP can activate Nuclear factor kappa-light-chain-
enhancer of activated B cells (NFkB), triggering a form of regulated necrosis named 
necroptosis [34]. 
6. Role of mitochondria in cell death 
MMP, a crucial event of the intrinsic mitochondrial apoptotic pathway, is considered a 
“point of no return” in the sequence of events leading to apoptosis. This phenomenon is 
associated with mitochondrial membrane potential loss (∆Ψm) that occurs as a result of 
assymetrical distribution of protons on both sides of the inner mitochondrial membrane. 
This irreversible process can take place before, during or after MOMP. The pore formation 
caused by Bcl-2 proteins induces MOMP, which leads to ∆Ψm dissipation, inhibition of ATP 
synthesis and ∆Ψm-dependent transport activities. Consequently, the respiratory change 
ceases, causing reactive oxygen species (ROS) generation and release of proteins confined 
within the inner mitochondrial space [35]. The contribution of the inner mitochondrial 
permeabilization, however, is controversial. MOMP can also result from the phenomenon 
called mitochondrial permeability transition that implies the opening of a non-selective pore 
in the inner mitochondrial membrane known as the mitochondrial permeability transition 
pore complex [12]. 
6.1. Mechanisms of MOMP 
Bax/Bak pore formation. The first proposed mechanism of MOMP is mediated by the Bcl-2 
family of proteins that directly act on the outer mitochondrial membrane. This family 
consists of about 17 members, some of which are proapoptotic and others antiapoptotic. The 
antiapoptotic members (Bcl-2, Bcl-xL, Bcl-w, Mcl-1, A1, Bcl-B, etc.) contain 3-4 BH domains 
(Bcl-2 homology regions: BH-1, BH-2, BH-3 and BH-4) and are named “Bcl-2 like” proteins. 
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Among the proapoptotic members, some contain 2-3 BH domains (Bax, Bak, Bok, etc.) and 
the “BH3-only” proteins (Bid, Bad, Bim, Bik, Bmf, Hrk, Bnip3, Noxa, Puma, Spike, etc.) have 
the biggest proapoptotic potential. BH-3 only proteins exert their effects either by inhibiting 
antiapoptotic Bcl-2 like members or by directly activating Bak and Bax. In the first 
mechanism, “facilitators” such as Bad interact with antiapoptotic Bcl-2 like proteins, 
dissociating them and creating MMP. In the second mechanism, however, “activators” such 
as truncated Bid (tBid) activate proapoptotic proteins by stimulating translocation of Bax to 
the mitochondrial membrane or by activating Bak [36].  
The interplay between antiapoptotic and proapoptotic proteins decides the final fate of the 
damaged cell. Antiapoptotic proteins can be found in the outer mitochondrial membrane, in 
the cytoplasm or in the Endoplasmic Reticulum (ER). Some propapoptotic members such as 
Bax or Bid reside in the cytosol, but translocate to the outer membrane upon triggering of a 
death stimulus, where they oligomerize to form a channel, either with themselves or with 
membrane anchored-Bak or tBid. The importance of the interactions between proteins and 
lipids is becoming more evident. In fact, it is now thought that Bak or Bax destabilize lipid 
bilayers instead of forming pores. BH3-only proteins activity is transcriptionally and 
posttranslationally regulated. Bid, for instance, is regulated by caspase-8, cathepsins, 
granzyme B or calpain [37-39]. The proapototic protein Bad in inhibited through 
phosphorylation by Akt and activated through dephosphorylation by calcineurin [40].  
 
Figure 4. Proposed model of mitochondria membrane permeabilization. Bax/Bak pore formation. Bcl-2 
family members regulation. 
Permeability transition pore complex. The second proposed mechanism of MOMP is based on 
the formation of the permeability transition pore (PTP) complex, a high conductance 
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channel which allows the influx of water and small solutes. PTP is a multiprotein complex 
located in the mitochondrial membrane that spans contact sites between the inner and the 
outer mitochondrial membranes. It is composed of three proteins: the voltage-dependent 
anion channel (VDAC), which is the most abundant protein of the outer membrane, the 
soluble matrix protein cyclophilin D (CypD), and the adenine nuclease translocase (ANT) 
located in the inner membrane. Other proposed PTP components are: hexokinase, creatine 
kinase and peripheral benzodiazepine receptor. The requirement of ANT is controversial. 
Distinct VDAC isoforms may interact with Bcl-2 members in a different manner. PTP 
opening leads to ∆Ψm dissipation, uncoupling of oxidative phosphorylation, water and ions 
influx, matrix swelling, outer membrane rupture and release of intermembrane space 
proteins, such as cytochrome c. Ca2+ favours PTP opening and permeability transitions are 
regulated by ∆Ψm, pH of mitochondrial matrix, redox potential, adenine nucleotides and 
bivalent metallic ions. PTP regulation by Bcl-2 proteins is still a matter of debate. It has been 
proposed that proapototic members promote pore opening, whereas antiapoptotic proteins 
favour pore closure [41]. Bcl-2 members can indirectly regulate PTP opening through Ca2+ 
efflux from the ER. In healthy cells, Bcl-2 or Bcl-XL can be located not only inserted in the 
mitochondrial outer membrane but also in the ER. Calcium ions exit the ER through inositol 
phosphate 3 receptors (IP3R), which can be blocked upon Bcl-2 binding. The proapoptotic 
members Bax and Bak induce Ca2+ movement from the ER to the mitochondrion [42]. 
However, Ca2+ interchange through PTP can be regulated by proapoptotic tBid [43,44].  
 
Figure 5. Proposed model of mitochondrial membrane permeabilization. Permeability transition pore 
complex. OM: outer membrane. IMS: intermembrane space. IM: inner membrane. VDAC: voltage-
dependent anion channel. HK: hexokinase. PBR: peripheral benzodiazepine receptor. CK: creatine 
kinase. ANT: adenine nuclease translocase. CypD: cyclophilin D (modified from Kroemer et al. 2007). 
The rise of mitochondrial matrix Ca2+ induces oxidative metabolism. However, upon 
apoptotic stimulus, Ca2+ can cause PTP opening, which can be transient and provide a fast 
calcium release mechanism, or persistent, giving rise to outer membrane rupture and release 
of apoptotic factors. Additionally, a different channel has been identified in the 
mitochondrion, composed of ceramide, a lipid that can form hydrogen bonds giving rise to 
ceramide structures that form channels which allow the efflux of proteins up to 60 kDa [42].  
 
Apoptosis and Medicine 
 
76 
6.2. Cell death effectors released from mitochondria 
The release of proteins from the intermembrane space and the loss of membrane-associated 
mitochondrial functions lead to cell death. Albeit is not clear the mechanism, mitochondrial 
destabilization provokes release of factors that mediate in caspase-dependent and 
independent pathways. 
Cytochrome c is a protein localized in the intermembrane mitochondrial space where it 
participates in the electron transport between complex III and IV of the mitochondrial 
respiratory chain. As already mentioned, cytochrome c is involved in the apoptosome 
formation and caspase cascade activation [45]. Cytochrome c release is a crucial step in the 
intrinsic apoptotic pathway. 
Smac/DIABLO means Second mitochondrial activator of caspases or Direct IAP Binding 
protein with LOw pI. This 29 kDa protein is also localized in the intermembrane space and 
is released to the cytosol upon activation by certain apoptotic stimuli, where it binds IAPs, 
preventing their function and favouring caspase activation. 
Omi/HtrA2 functions in a similar way to Smac/Diablo. This 36 kDa protein belongs to a 
highly conserved protein family. In healthy cells, Omi/HtraA2 is located in the 
intermembrane space. Upon apoptotic triggering (TRAIL, UV radiation, staurosporine, etc.) 
is released to the cytosol where it binds and inactivates IAPS promoting caspase activation. 
In addition, to the caspase-dependent effectors already mentioned, other caspase-
independent proteins can be activated: 
AIF stands for Apoptosis Inducing Factor. AIF is a 57 kDa flavoprotein localized in the 
intermembrane space whose aminoacid sequence resembles ferrodoxin. AIF is expressed as 
a 67 kDa precursor that possesses two mitochondrial localization sequences in its amino-
terminal end. Once in the mitochondria, AIF precursor is cleaved giving rise to the mature 
protein that is believed to have an oxidoreductase function based on its FAD domain, 
playing an important physiological role in oxidative phosphorylation. AIF translocates to 
the nucleus in response to apoptotic stimuli where it induces chromatin condensation and 
large-scale (50 Kbp) DNA fragmentation by an unknown mechanism, leading to apoptosis 
in a caspase-independent fashion. It has been recently suggested that Steroid receptor 
coactivator-interactive protein prevents AIF release from the mitochondria [46]. Conversely, 
calcium-activated calpain promotes AIF release from the mitochondria [47] and poly-ADP-
ribose-plymerase 1 (PARP-1) activity is necessary for AIF translocation to the nucleus [48]. 
Endo G or Endonuclease G also participates in caspase-independent cell demise 
mechanisms. It belongs to a family of Mg2+-dependent endonucleases. Endo G is a 30 kDa 
mitochondrial protein that, like AIF, is synthesized as a precursor form and its 
mitochondrial localization sequence is cleaved when the protein reaches the intermembrane 
space. Endo G is released from the mitochondria upon certain apoptotic stimuli such as UV 
radiation or anti-Fas antibodies, and it translocates to the nucleus, where it cleaves 
chromatin DNA into nucleosomal fragments. Endo G cooperates with exonucleases and 
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DNase I in order to facilitate DNA processing. Endo G nuclease activity has been observed 
even in the presence of caspase inhibitors. Therefore, similarly to AIF, Endo G participates 
in caspase-independent cell death mechanisms. The physiological role of Endo G, however, 
needs to be established. 
Besides its function as IAP inhibitor, Omi/HtrA2 has been implicated in caspase-
independent cell death mechanisms by virtue of its serine protease activity. This effector 
molecule cleaves proteins such as ped/pea-15 [49], HAX-1 [50], or RIP-1 [51]. However, the 
exact mechanism as to how this occurs is still unknown. 
AIF and Endo G activity together with Omi/HtrA2 serine protease activity are considered 
responsible for the recently called caspase-independent intrinsic apoptosis [11]. 
6.3. Afferent signals from other organelles 
Mitochondria play a central role in programmed cell death pathways and integrate different 
signals coming from other organelles, being MMP, a point of no return, as already 
mentioned. 
6.3.1. Nuclear DNA damage 
The tumour suppressor p53 mediates DNA damage response, either by stimulating DNA 
damage response or by inducing apoptosis. As a transcription factor, p53 transactivates Bcl-
2 proteins (Bad, Bid, Puma and Noxa) [52], which induce MMP and release of proteins from 
the intermembrane space [12]. After DNA damage, p53 can also induce the expression of 
p53-induced protein with a death domain (PIDD), which activates nuclear caspase-2. PIDD 
associates with RAIDD, forming a signalling platform known as the PIDDosome [53]. The 
PIDDosome can activate caspase-2 and the transcription factor NFkB in response to DNA 
damage [54]. Caspase-2 acts upstream of the mitochondria by inducing Bid cleavage, Bax 
translocation and cytochrome c release. The role of caspase-2 in apoptosis, however, is 
controversial. It is now thought that caspase-2 functions as a tumour suppressor gene 
regulating the cell cycle machinery [55]. p53 may also induce apoptosis by transcription-
independent mechanisms, for instance, by directly interacting with Bak, Bax, Bcl-2 and Bcl-
XL at the outer mitochondrial membrane [56]. The activity of p53 can be promoted by 
glycogen synthase kinase 3β (GSK3β) binding both in the nucleus and in the mitochondria, 
which in turns promotes cytochrome c release and caspase-3 activation [57].  
6.3.2. Endoplasmic reticulum: Unfolded protein response 
The ER has primordial roles in normal physiological and survival processes. These include 
intracellular calcium homeostasis, protein secretion and lipid biosynthesis [58]. Apoptosis 
can be initiated as a consequence of stress in the ER. This stress condition can be caused by 
calcium homeostasis alteration, glucose deprivation, hypoxia, low redox potential, excessive 
protein synthesis or defective protein secretion. These insults can cause accumulation of 
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unfolded proteins in the lumen of the ER, triggering an evolutionary conserved signalling 
pathway known as the Unfolded Protein Response (UPR) which can culminate in cell death. 
UPR consists of global protein synthesis reduction, synthesis induction of chaperones and 
other proteins related to protein folding and retro-translocation of misfolded or unfolded 
proteins from the ER to the cytosol, where they will be degraded by the proteasome [59]. 
When the ER stress is sustained and ER function cannot be restored, UPR activates a specific 
apoptotic pathway. Caspase-12, which is localized in the ER, is activated by calcium-
dependent proteases known as calpains [60]. Once activated, caspase-12 activates caspase-9 
without apoptosome intervention [61,62]. It has been postulated that ER stress can also 
activate caspase-8, which induces cytochrome c release through Bid processing [29,63]. In 
addition, ER stress can also initiate autophagy, a different type of cell death. 
6.3.3. Lysosomes 
Lysosomes are organelles that contain acidic hydrolases such as cathepsins. Rupture of 
lysosomes release cathepsins to the cytosol, where they can trigger apoptosis or necrosis. 
Cystatins, on the other hand, are cytosolic proteins that act as negative regulators of 
cathepsins when they are translocated from lysosomes to the cytosol. Apoptosis initiated in 
lysosomes follows a mitochondrion-dependent pathway associated to caspase activation. 
However, it has been shown that cathepsin D activates Bax and AIF release, triggering a 
caspase-independent apoptotic pathway [37]. Furthermore, some cathepsins induce Bid 
cleavage [38], interaction with Bcl-2 proteins and permeabilization of the mitochondrial 
membrane [64]. In addition, cathepsins can alter mitochondria functions by cleaving 
subunits of the oxidative phosphorylation complexes, inducing ROS generation [12]. 
Lysosomes are essentially involved in autophagic cell death mechanisms. 
6.3.4. Cytosol 
Several signals coming from the cytosol can induce MMP. These include: metabolites such 
as glucose 6-phospate and palmitate, ROS and activation of certain kinases: GSK3β, protein 
kinase C (PKC) δ, [65] and members of the JNK signalling pathway [38,66]. On the other 
hand, other molecules inactivate PTP and protect mitochondrial membrane from 
permeabilization, inhibiting apoptosis. These include: metabolites (ATP, glucose, NADH, 
UTP, etc.), antiapoptotic Bcl-2 family members, antioxidant enzymes such as glutathiones S 
transferase and prosurvival kinases such as Akt. In this sense, Akt can inhibit apoptosis by 
several mechanisms: activation of NFkB [67], inactivation of GSK3β and caspases and 
through hexokinase II-dependent mechanisms [12]. 
6.3.5. Cytoskeleton 
The cytoskeleton is composed of microtubules, microfilaments and intermediate filaments 
that play important roles in cell motility, polarity, attachment, shape maintenance, etc. 
Adherent cells can undergo a specific type of caspase-dependent cell death called anoikis 
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when they become detached from the extracellular matrix or neighbouring cells [68,69]. 
Besides its well-established role in mitosis, cytoskeleton components can modulate 
mitochondria. For example, microtubules sequester BH3-only proteins Bim and Bmf, which 
interact with dynein [70]. Gelsolin has anti-apoptotic effect by closing the VDAC channel 
[71]. Actin can also modulate VDAC closure [69,72]. 
7. Parp proteolysis as an indicator of cell death 
Poly-ADP-Ribose Polymerase (PARP) is a family of 16 nuclear enzymes, among which, the 
best characterized is PARP-1. PARPs have several functions in cell proliferation, cell death, 
DNA recombination and DNA repair. PARP-1 is a 116 kDa nuclear protein involved in 
DNA repair mechanisms. PARP synthesis is activated when DNA is fragmented in the 
presence of nuclear poly-ADP ribosylated proteins. In an early apoptotic stage, caspases 
cleave PARP resulting in an 89 kDa and a 24 kDa fragments [73]. The smaller fragment 
irreversibly binds DNA fragment ends, impeding the access of DNA repair enzymes. Hence, 
PARP proteolysis facilitates nuclear disorganization and ensures irreversibility of the 
apoptotic process [74]. PARP cleaves also takes place during necrosis. However, the 
fragments obtained are of different size [75]. A role of PARP cleavage in autophagy induced 
by DNA damage has been recently suggested [76]. Parthanatos is a particular case of 
regulated necrosis in which PARP activation plays an important role. PAR polymer, the 
product of PARP-1 activation, translocates to the mitochondria and induces AIF release. 
Subsequently, AIF translocates to the nucleus and provokes chromatin condensation and 
DNA fragmentation [77]. Necroptosis or regulated necrosis also involves PARP activation 
[78]. Therefore, PARP can participate in different types of cell death and it is not exclusive of 
apoptosis, as previously thought. 
8. Autophagy 
Autophagy is a self-digestive physiological process that occurs in all eukaryotic cells, during 
which long-lived proteins and organelles are degraded by lysosomes to maintain cellular 
homeostasis [79]. To date, at least three types of autophagic pathways have been described: 
macroautophagy (simply called ‘‘autophagy’’), microautophagy and Chaperone-Mediated 
Autophagy (CMA). These forms differ in the mode the cargo is delivered to the lysosome. 
Macroautophagy is a dynamic process in which portions of the cellular cytoplasm and 
organelles are sequestered in a double-membrane bound vesicle called autophagosome, 
which then fuses with the lysosome [80,81]. Microautophagy involves the sequestering by 
the lysosome itself of part of the cytoplasm. During microautophagy, the membrane of the 
lysosome invaginates, and then pinches off to form an internal vacuole that contains 
material derived from the cytoplasm [82]. The notable difference between macroautophagy 
and microautophagy is that in the latter, part of the cytoplasm is directly taken up into the 
lysosome. Both macroautophagy and microautophagy are basically nonselective 
degradation pathways in which bulk cytoplasm is randomly sequestered. However, in some 
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cases, autophagy can selectively eliminate some organelles, such as damaged peroxisomes, 
mitochondria or ER. In contrast, CMA does not involve vesicular traffic and is specific for 
the degradation of proteins. During this process, proteins are delivered to lysosomes with 
the help of molecular chaperones and a lysosomal receptor. Cytosolic proteins with a 
specific peptide sequence motif (‘‘KFERQ’’ motif) are recognized by a complex of molecular 
chaperones (Hsc70) and then bind to a lysosomal receptor called lysosome associated 
membrane protein (LAMP) type 2a [83].  
Macroautophagy (hereafter referred to as autophagy) is the most studied and prevalent 
form of autophagy in cells. This process begins with the formation of a “C” shaped double-
membrane structure in the cytosol, called “omegasome”, which is formed from the ER 
(Initiation phase). Following this, the omegasome grows to form the “isolation membrane”, 
which elongates to engulf cytoplasmic components (Elongation phase). Then, the “isolation 
membrane” curves and closes to form a vacuole called the autophagosome (Maturation 
phase). As a result, portions of the cell cytoplasm and some organelles are sequestered in 
this vacuole. Finally, the outer membrane of the autophagosome fuses with the lysosomal 
membrane and the inner membrane (the autophagic body) carrying the cytosolic 
constituents enters the lysosome. The autophagic body is degraded in the lysosome by 
hydrolases and the resulting free amino acids and macromolecules are transported back into 
the cytosol for reuse [84]. In this way, autophagy contributes to the maintenance of the 
cellular energy homeostasis, to the clearance of damaged organelles and to adaptation to 
environmental stresses [85]. Accordingly, autophagy defects have been linked to a wide 
range of human pathologies, including cancer. 
 
Figure 6. Autophagy. Three different forms of autophagy are depicted: Macroautophagy, 
Microautophagy and Chaperone-mediated autophagy (CMA) (taken from Yen and Klionsky, 2008). 
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9. Mitotic catastrophe 
The cell death process that takes place when mitosis cannot be completed is called mitotic 
catastrophe. This phenomenon is triggered as a consequence of perturbations of the mitotic 
machinery that governs appropriate chromosome segregation. The main hallmark of mitotic 
catastrophe is the enlarged cell size accompanied by multinucleation [5]. Other features are 
chromatin condensation, DNA degradation, MMP, cyrochrome c release from the 
mitochondria and caspase activation [86]. Some types of mitotic catastrophe, however, take 
place without intervention of caspases, what has been named caspase-independent mitotic 
death [87]. Mitotic catastrophe results form the combination of deficient checkpoints (DNA 
and mitotic spindle) and DNA damage. Cells that evade the mitotic checkpoint and do not 
undergo apoptosis are prone to generate aneuploidy. Therefore, mitotic catastrophe is 
conceived as a device to avoid genomic instability. The players that take part in mitotic 
catastrophe are: cell cycle-dependent kinases (Cdk1, Aurora, Plk), cell cycle-check points 
proteins (Chk2, p53, p73), survivin, MCl-2, Blc-2 proteins, caspase-2, etc. [86]. Mitotic 
catastrophe is a poorly defined molecular signalling pathway that precedes apoptosis, 
necrosis or senescence [88].  
 
Figure 7. Mitotic catastrophe. a) In the absence of perturbations cells progress normally. A mitotic 
defect is detected and: b) cells die without exiting mitosis, c) cells undergo mitotic arrest, exit mitosis 
(mitotic slippage), reach the subsequent G1 and die or d) undergo senescence (taken from Galluzzi et al. 
2012). 
10. Necroptosis 
Necrosis is characterized by plasma membrane permeabilization, swelling and rupture. 
Necrosis can be accompanied in many instances by release of lysosomal hydrolases. 
Recently, a novel form of regulated necrosis has emerged and has been named necroptosis 
[78]. This cell death modality presents morphological features of necrosis but is regulated by 
signalling pathways and catabolic mechanisms. The most studied necroptotic pathway is 
mediated by the death receptor TNFR1 and inhibited by necrostatin-1. Upon TNF binding, 
TNFR1 undergoes a conformational change and recruits TRADD, TRARF2, cIAP1, cIAP2 
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and RIP1 to form complex I. RIP1 is polyubiquinated by cIPA1 and cIAP2 and activates the I 
Kappa B kinase (IKK) complex, triggering NFkB activation. RIP1 can be deubiquitinated by 
cylindromatosis D (CYLD) and together with RIP3 forms the complex II which also contains 
TRADD, FADD, and caspase-8. Subsequently, caspase-8 cleavage will induce apoptosis, 
whereas caspase-8 inhibition by caspase inhibitors (zVAD-fmk) for example, will favour 
necroptosis [89]. A novel death regulation platform named ripoptosome has recently been 
described. Unlike complex II, the ripoptosome  forms independently of death receptors, is 
activated by genotoxic stress or IAP antagonists and is tightly regulated by IAPs (ciAP1, 
cIAP2, xIAP) or cellular FLICE-like inhibitory protein (FLIP), a catalytically inactive 
homologue of caspase-8 [78,90,91]. The executioner mechanisms of necroptosis are unclear. 
However, in some cases the necroptotic process involves ROS generation, lysosomal 
membrane permeabilization, AIF release from the mitochondria and PARP activation. When 
caspase activation is not involved, necroptosis is associated with formation of autophagic 
vesicles [92,93]. 
 
Figure 8. TNFR1-mediated apoptosis and necroptosis (taken from Long and Ryan 2012). 
11. Apoptosis, chemoresistance and cancer 
So far, we have reviewed generalities of different modalities of cell death that can take place 
after various pathologies: inflammation, stroke, ischemic injury, neurodegenerative 
disorders, viral infection, neoplasia, etc. The implication of apoptosis in cancer was initially 
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observed as the type of cell death occurring in untreated tumours and in tumour regression 
after radiotherapy [4]. The oncogenic process requires accumulation of diverse alterations 
within a cell that disrupt its normal homeostasis of cell death and growth. It is well 
established that excessive proliferation is not only due to oncogene activation but also to 
failure of the pathways controlling programmed cell death mechanisms [94]. A malignant 
cell can be protected from cell demise though expression and/or activation of antiapoptotic 
factors (acting as oncogenes) or through inactivation of antiapoptotic factors (acting as 
tumour suppressor genes). Evasion of apoptosis is a hallmark of cancer [95]. Dysregulation 
of apoptotic pathways renders cells resistant to antitumour strategies since the final 
outcome of radio and chemotherapy is frequently apoptosis of cancer cells. Therefore, 
resistance to cell death- in particular apoptotic cell death- is an important aspect of 
carcinogenesis, as it confers resistance to anticancer agents [96]. In many tumours, 
chemoresistance acquisition is due to upregulation or modification of key elements of 
apoptosis control, such as Bcl-2, Bcl-XL and IAP family members [36]. Other mechanisms are 
characterized by inactivating mutations in proapoptotic proteins, such as p53. 
Bcl-2. The first apoptotic gene related to neoplasia was the apoptotic inhibitor bcl-2. 
Therefore, Bcl-2 overexpression can contribute to tumour cell survival. Indeed, it was 
discovered at the breakpoint of the t(14;18) chromosomal translocation occurring in 
follicular lymphomas and leukemias [97,98]. Bcl-2 is the first oncogene that acts by 
inhibiting cell death instead of stimulating cell proliferation. In this respect, it was shown to 
cooperate with myc in immortalization of lymphoid cells [99] and in lymphomagenesis in 
transgenic mice [100]. Furthermore, it has been shown that Bcl-2 overexpression can confer 
multidrug resistance (MDR) phenotype and evasion of apoptosis to tumour cells exposed to 
serum deprivation, certain toxins or chemotherapeutic agents [101]. Mcl-1 and Bcl-XL have 
been shown to play important roles in tumourigenesis as well. Bcl-2 overexpression can also 
be the result of gene amplification or reduced expression of  micro RNAs (miRNAs) in 
cancer cells [102].  
BH3-only proteins. Loss or suppression of proaptotic proteins is frequent in cancer. Bax 
frameshift mutations appear in 50 % of colon carcinomas with DNA mismatch repair defects 
[103]. In addition, 17% of mantel cell lymphoma has homozygous Bim deletions [104], Bok 
and Puma suffer allelic deletions [105], and Bim and Puma are silenced by 
hypermethylationin Burkitt lymphoma [106,107]. Bim expression can also by silenced by 
miRNAs in several types of cancers [102]. Some BH-3 only proteins (Bim, Puma and Bmf) 
are necessary to initiate apoptosis in response to certain antineoplasic drugs [101].  
XIAP. The X-linked inhibitor factor of apoptosis (XIAP) belongs to the IAP protein family. 
XIAP can render chemoresistance to cancer cells by inactivating caspases. XIAP 
overexpression is frequent in several tumour types [108]. Since XIAP is the only protein 
capable of inactivating both initiator and executioner caspases, it has become a putative 
biomarker of chemoresistance. It is the only IAP member capable of blocking active caspases 
[109]. However, XIAP has other roles in malignant transformation apart from preventing 
apoptosis. XIAP is involved in NFkB, MAPK and ubiquitin-proteasome pathways [108]. 
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Survivin. This protein is a member of the IAP family that inhibits apoptosis by inactivating 
caspases [110] and stimulates DNA repair upon binding to DNA-PK in glioblastoma cell 
lines [111]. In addition, survivin plays a role in regulation of the mitotic checkpoint. Survivin 
expression is deregulated in cancer through several mechanisms: amplification of the locus 
on chromosome 17q25 [112], exon demethylation [113], or increased promoter activity [114]. 
Overall, survivin overexpression is an unfavourable prognostic marker and correlates with 
poor prognosis [110]. It is also involved in angiogenesis [115], tumour progression and 
chemoresistance. It has been shown that survivin inhibition sensitizes tumour cells to 
paclitaxel, cisplatin, etoposide, gamma radiation and immunotherapy [116]. 
p53. Inactivating mutations in the tumour suppressor p53 account for about 50% of human 
tumours and are associated with poor prognosis. One role of p53 is the regulation of cell 
cycle through the DNA damage response. Many chemotherapeutic agents cause DNA 
damage and activate p53. As a result, the cdk inhibitor p21 can be transcriptionally activated 
causing cell cycle arrest or Bax can be activated by translocation to the mitochondria 
inducing apoptosis [56]. When p53 is not mutated, cells showing DNA damage induced by 
genotoxic stress that cannot be repaired during cell cycle arrest, are induced to apoptosis 
through p53 activation of the mitochondrial pathway, mostly increasing transcription of the 
BH-3-only proteins, Bid, Noxa and Puma [52]. In addition, p53 can activate genes of the 
extrinsic pathway: TRAIL-R2 (DR5) and Fas (CD95/Apo-1) [117]. 
 
Figure 9. Transcription-dependent and independent effects of p53 activation  
11.1. Defective checkpoints 
p53 and the DNA damage response. DNA damaging agents can induce different types of 
lesions that culminate in cell death. DNA damage is detected by sensors within the cell that 
relay a signal causing cell cycle arrest and DNA repair or apoptosis. These networks of 
genome surveillance are known as replication checkpoints. When DNA damage is low the 
lesions can be repaired by several mechanisms. On the other hand, when the DNA damage 
is high or persistent, the cell undergoes apoptosis [118]. For example, as a response to 
genotoxic insults, p53 is phosphorylated by Checkpoint kinase 1 (Chk1) and Checkpoint 
kinase 2 (Chk2) and cannot be ubiquinated by mdm2 and becomes stabilized. Consequently, 
p21 is activated and cells are arrested either in the G1 or the G2 phase of the cell cycle. 
Conversely, if p21 is absent, apoptosis prevails. Therefore, p21 is critical in maintaining the 
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balance between cell cycle arrest and apoptosis. The frequent loss of p53 in cancer 
enhances its ability to survive after DNA damage and evade apoptosis. When p53 is 
mutated, the response to DNA damage depends on mechanisms regulated by Ataxia 
telangiectasia mutated (ATM) and Ataxia telangiectasia and Rad3 related (ATR) 
independent of p53, which regulate Chk1 or Chk2 [119]. These kinases in turn activate 
NFkB, Akt and survivin [120].  
Cell cycle checkpoints. Checkpoints are mechanisms that respond to internal or external stress 
by activating machineries that arrest the cell cycle at particular points (G1/S, intra-S-phase, 
G2/M, or mitotic spindle). Many tumour suppressor genes are components of DNA damage 
or cell cycle checkpoints: p53, Retinoblastoma (Rb), ATM, p16, BRCA1/2, etc. The frequency 
of tumour suppressor loss in cancer cells provides an advantage to their growth. The G1 
checkpoint is controlled by Rb, which in turn, is phosphorylated by cdk’s. One cdk inhibitor 
is p16. Both Rb and p16 are frequently mutated in diverse types of cancer. The mitotic 
checkpoint utilizes genes (Mad, Bub, Aurora kinases) to detect spindle defects. When the 
cell is not able to surpass the damage, it undergoes mitotic catastrophe. In addition, loss of 
checkpoint controls increases genomic stability, providing cancer cells with adaptive or 
evolutionary advantages [121].  
 
Figure 10. DNA damage and cell cycle checkpoints 
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Figure 11. Akt signalling pathway 
Akt. Classically, the phosphoinositide-3-kinase (PI3K)-Akt-mTOR pathway is described as a 
key signal transduction cascade that integrates signals from growth factors and nutrients to 
regulate cell growth and proliferation [122]. Following growth factor binding to cell surface 
receptors, PI3K is activated and phosphorylates phosphatidylinositol-4,5-biphosphate (PIP2) 
to generate the second messenger phosphatidylinositol-3,4,5-trisphosphate (PIP3). This 
process can be inhibited by the tumour suppressor protein phosphatase and tensin homolog 
(PTEN), which dephosphorylates PIP3 and terminates PI3K signalling. Then, the 
accumulated PIP3 recruits PDK1 and Akt through their Pleckstrin homology domains, and 
Akt is activated [123]. Akt recognizes and phosphorylates a consensus sequence that is 
present in many proteins. These substrates control key cellular processes such as apoptosis, 
cell cycle progression, transcription, and translation, all of which are critical events in cancer 
[124]. The Akt signal transduction pathway is probably the best survival pathway 
characterized. Moreover, Akt is constitutively activated in several malignant tumours, such 
as prostate, breast, ovary, lung and liver carcinomas [125]. Akt suppresses apoptosis 
through different mechanisms, including phosphorylation of forkhead transcription factors, 
which regulate proapoptotic proteins such as Bim and Fas ligand. The phosphorylated 
forkhead proteins are trapped in the cytosol and cannot enter the nucleus. Akt also 
phosphorylates and inactivates several proapoptotic proteins like Bad and caspase-9. 
Importantly, it activates IKK inducing the transcription factor NF-κB, leading to 
transcription of several antiapoptotic proteins such as Bcl-xL, and XIAP [96,126]. Akt also 
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prevents the nuclear localization of p53 upon binding and phosphorylation of mdm2 [120]. 
Therefore, deregulation of the PI3K-Akt pathway can be considered as a cause of 
chemoresistance [127]. 
11.2. Immunogenecity of cancer cell death 
It is becoming more evident that the immune response facilitates the effects of 
chemotherapy. Physiological death avoids autoimmunity. However cancer cell death 
triggered by radiotherapy or some chemotherapeutic agents such as anthracyclines can be 
immunogenic [128]. Immunogenic death involves changes in the composition of the cell 
membrane and the release of molecules called Damage Associated Molecular Patterns or 
alarmins. In particular, calreticulin has been shown to be crucial for immunogenic cancer 
cell death [129]. The immune system determines the long-term success of antitumor 
therapies. It seems that mitochondrial events as well as the ER response in conjunction with 
autophagy can establish whether cancer cells die in response to chemotherapy [130]. It has 
been found that calreticulin is the dominant pro-phagocytic signal on several cancers 
including neuroblastoma, non Hodgkin’s lymphoma and bladder cancer. However, 
calreticulin is counterbalanced by the “don´t eat me” signal CD47, which prevents cancer 
cell phagocytosis and is also highly expressed in these tumours [131]. Moreover, since CD47 
is expressed on the surface of all human cancer cells but not in normal cells, blocking CD47 
function with antibodies is emerging as a novel potential cancer strategy [132]. 
12. Senescence and cancer 
We have already mentioned that strong p53 activation induces apoptosis. However, 
Leontieva and colleagues have shown that a weak and sustained p53 activation during cell 
cycle arrest can promote a different type of cell demise known as senescence [133]. Cellular 
senescence, induced after an irreversible cell cycle arrest, is a protective mechanism that 
limits proliferation of cells exposed to endogenous or exogenous insults. This cell death type 
can take part in processes of tumour suppression, tumour promotion, aging, and tissue 
repair [134]. Senescent cells become flattened and enriched with vacuoles. Some of the 
biochemical changes characteristic of senescence include elevation in β-galactosidase 
activity at an acidic pH, increase in senescence markers (p16, p15, p21, p53, ARF, etc.), 
heterochromatinization and, similarly to autophagy, formation of autolysosomes. It has 
been recently shown that chemotherapeutic agents may cause a form of “premature 
senescence” that can be considered as a tumour suppressor mechanism. Therefore, the 
induction of premature senescence as a drug-inducible arrest program has therapeutic 
potential for cancer treatment, but requires further investigation [135]. 
13. Autophagy and cancer 
Regarding the role played by autophagy in cancer, mounting evidences suggest that 
autophagic cell death functions as a tumour suppressor mechanism. Several tumour 
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suppressor proteins have been shown to induce autophagy. Supporting this idea, there are 
also several works showing that certain oncogenic proteins inhibit autophagy. Most of this 
oncogene products form part of the classic PI3K-Akt-mTOR pathway. In the following 
section, we summarize the literature on the role played by key tumour suppressors and 
oncogene products in the regulation of autophagy and the involvement of autophagic genes 
in cancer. 
13.1. Tumour suppressor genes that regulate autophagy 
To date, several tumour suppressor proteins that regulate autophagy have been described. 
These include: Beclin 1, UV irradiation-resistance-associated gene (UVRAG), PTEN, Bcl-2, 
and p53. The majority of them act as autophagy inducers with the exception of p53 that is 
able to activate or inhibit autophagy.  
Role of Beclin 1 in autophagy: Beclin1 is a key regulator of autophagy. It regulates the 
autophagic process at different levels by combining with the enzyme class III PI3K (PI3KC3) 
and specific group of proteins forming unique class III PI3K-Beclin complexes. This PI3KC3-
Beclin complex functions as a core complex during autophagy [136,137] by phosphorylating 
phosphatidylinositol to produce phosphatidylinositol 3-monophosphate, which presumably 
allows the recruitment of essential autophagy related (Atg) proteins to the membrane. In 
mammals, at least three types of class III PI3-kinase-Beclin complexes contribute to 
autophagy [84,138,139]. 
Role of Beclin 1 in tumour suppression vs. autophagy: The first link between autophagy and 
cancer was established in 1999, when Liang and colleagues discovered that the autophagic 
protein Beclin 1 was able to inhibit tumourigenesis [140]. Beclin 1 is a tumour suppressor 
gene [141,142] monoallelically deleted in many types of cancers, including ovary (75%), 
breast (50%) and prostate (40%). Several studies suggest that the activation of autophagy by 
Beclin 1 is tightly associated with its tumour suppression function. For example, 
overexpression of Beclin-1 in the human MCF-7 breast carcinoma cell line is associated with 
inhibition of cell proliferation and induces autophagy [140]. In contrast, studies in vivo 
demonstrate that the monoallelic disruption of Beclin 1 gene promotes cellular proliferation 
and reduces autophagy [142]. Furthermore, genetically engineered mouse models with 
heterozygous disruption of Beclin 1 have decreased autophagy and are more prone to 
develop tumours, including lung carcinomas, hepatocellular carcinomas, lymphomas and 
mammary precancerous lesions [141,143]. Taken together, these studies firmly support the 
notion that autophagy induction and tumour inhibition function of Beclin 1 are closely 
interconnected. 
UVRAG is another tumour suppressor protein that is able to activate autophagy. UVRAG is 
a positive regulator of Beclin 1, as it promotes its binding to PI3KC3 to form the complex 
and enhance Beclin 1 activity. Through mediating Beclin 1-PI3KC3 complex, UVRAG can 
promote autophagy, thus inhibiting carcinogenesis of human colon cancer cells. It has also 
been proposed that UVRAG is involved in causing membrane curving [144]. Furthermore, 
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the monoallelic deletion or mutation of UVRAG has been observed in several human 
cancers such as colon, gastric and breast cancer [145-147]. 
Bif-1 is also a tumour suppressor that promotes autophagy. Similar to UVRAG, Bif-1 is a 
positive regulator of Beclin 1, as it enhances its interaction with PI3KC3, thus increasing 
autophagy. Consistently, it has been shown that loss of Bif-1 prevented the formation of 
autophagosomes and induced the development of spontaneous tumours in mice [144]. 
Furthermore, expression of Bif-1 is significantly reduced in prostate, colon, urinary bladder 
and gastric tumours [146,148,149]. The precise mechanism of Bif-1 in suppressing 
tumourigenesis has not been fully clarified, but it is reasonable to presume that its tumour 
inhibitory activity is associated with its role in inducing autophagy. Some groups have also 
suggested that Bif-1 suppresses tumour growth through its interaction with proapoptotic 
Bax [150]. 
13.2. Oncogenic genes that regulate autophagy 
Most of the oncogenic genes that regulate autophagy described to date are key proteins of 
the PI3K-Akt-mTOR pathway. These proteins inhibit autophagy and promote 
carcinogenesis.  
mTOR: the best-studied downstream substrate of Akt is the serine/threonine kinase 
mammalian target of rapamycin (mTOR). In mammals, mTOR exists in two different 
complexes, known as mTORC1 and mTORC2. In the mTORC1 complex, mTOR is bound to 
a protein called Raptor, and in the mTORC2 complex, mTOR is bound to Rictor. mTORC1 is 
best known for its role in regulating protein synthesis through two of its substrates, 4E-BP1 
and p70S6K [151]. Akt can directly phosphorylate and activate mTOR, or activate it 
indirectly by phosphorylation and inactivation of TSC2. When TSC2 is inactivated by 
phosphorylation, it can no longer associate with TSC1, thus abolishing the inhibitory effect 
of TSC1-TSC2 complex on mTORC1. As a result, mTOR is activated and signals to its 
downstream targets p70S6 kinase, ribosomal protein S6 and 4EBP-1/eIF-4E to control protein 
translation and proliferation [152]. mTORC1 is not only a key regulator of proliferation and 
survival, but also a master inhibitor of autophagy. Under nutrient-rich conditions, mTORC1 
is activated and phosphorylates ULK1, ULK2 and mAtg13, inhibiting the initiation of 
autophagy. In contrast, in nutrient starvation conditions mTORC1 is inactivated and 
dissociates, resulting in activation of ULK1 and ULK2, which initiates the autophagy 
cascade [151]. The PI3K-Akt-mTOR pathway is probably the most commonly activated 
signalling pathway in human cancers [124]. This route is activated aberrantly in many types 
of tumours, and hence, inhibited autophagy and increased proliferation and protein 
synthesis are often observed. For example, many human cancers are characterized by 
activating mutations in specific components of the signalling pathway that connect Receptor 
tyrosine kinases to mTOR, including Ras, PI3K and Akt. Somatic mutations in PIK3CA gene 
encoding the catalytic subunit of class I PI3K frequently occur in cancers of colon, breast, 
brain and lung [153]. PTEN, another regulator of PI3KI-Akt pathway, is a tumour 
suppressor that is found to be mutated in many types of cancer.  
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Bcl-2 forms part of the Bcl-2 family proteins. For almost two decades, Bcl-2 has been 
regarded to function as an antiapoptotic protein that contributes to tumourigenesis. The role 
of Bcl-2 in autophagy was realized in 1998 when Liang identified Beclin 1 as Bcl-2 
interacting protein [140]. Bcl-2 acts as a negative regulator of autophagy by inhibiting Beclin 
1. It binds constitutively to Beclin 1, blocking the interaction between Beclin 1 and PI3KC3 
[154-156]. As a result, PI3KC3 activity is decreased and autophagy is downregulated [155]. 
The binding of Bcl-2 with Beclin 1 seems to be constitutive, and its detachment from Beclin 1 
is speculated to be essential in autophagy. 
13.3. How does autophagy suppress tumourigenesis? 
The combined data presented above strongly support the idea that autophagy functions as a 
tumour suppressor process. Consistent with this, oncogenes that have a role in autophagy 
are potent inhibitors of this process. Although the molecular mechanisms by which 
autophagy functions in tumour suppression are poorly defined, at least two mechanisms 
have been described: 
a. Autophagy maintains the integrity of the genome 
The first hypothesis is that autophagy may function as a housekeeping pathway to exert the 
quality control of organelles, proteins and DNA. Mathews and colleague observed that in 
autophagy deficient tumour cells, metabolic stress promotes the accumulation of p62, 
damaged mitochondria and ROS generation, promoting genomic instability and leading to 
oncogene activation and tumour progression [157,158]. Furthermore, immortalized mouse 
epithelial cells with a defect in ATG genes (loss of Beclin 1 or Atg 5) display increased DNA 
damage, centrosome abnormalities, numerical and structural chromosomal abnormalities 
and gene amplification, especially after ischemic stress.  
However, the mechanisms through which autophagy preserves the integrity of the genome 
remains elusive. One possibility could be that autophagy may contribute to cell cycle 
regulation, for example by degrading organelles and/or proteins involved in the cell cycle 
checkpoints [159]. Another possibility is that autophagy might simply function at a more 
general level to ensure the minimal amount of ATP and other metabolites required for DNA 
repair. Finally, autophagy may act by removing old and/or damaged organelles (for 
example, uncoupled mitochondria) which may act as a source of genotoxic chemical species 
such as ROS. 
b. Autophagy limits necrosis-mediated inflammation 
Necrosis normally results from physical injury in which the cell lyses and releases its 
intracellular contents, which activate the innate immune system and a wound-healing 
response [160]. As a result, inflammatory cells are recruited and cytokines are released to 
promote cell growth to replace the damaged tissue [161,162].  
In contrast, apoptosis may be the preferred means of cell demise for cells upon metabolic 
stress, as cells are eliminated without inflammation. However, in cancer cells with a defect 
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in apoptosis, autophagy is induced for cell survival. Through autophagy, cells eliminate 
damaged organelles and may maintain their normal cellular function under adverse 
conditions of fluctuating oxygen and nutrient supply. However, this beneficial effect of 
autophagy functions during short term interruptions in nutrient availability, as in the long 
term (excess of autophagy) it can possibly lead to cell death.  
A high proportion of tumours have been seen to present a defect both in autophagy and 
apoptosis. Degenhardt and colleagues have shown that the inhibition of both processes 
under conditions of metabolic stress generates a necrotic cell-death, suggesting that 
apoptosis and autophagy function to limit necrosis [163]. In these necrotic tumours a 
persistent inflammatory infiltration and cytokine production exists, which is thought to 
promote tumour growth and thus, is associated with poor prognosis.  
13.4. Role of autophagy in tumour survival 
The data presented above strongly supports the idea that autophagy functions as a tumour 
suppressor process and that inhibition of autophagy leads to carcinogenesis. However, there 
are some circumstances where autophagy contributes to tumour survival promoting 
carcinogenesis: 
a. Autophagy is induced by nutrient starvation  
The survival role of autophagy during nutrient limitation is well established. When cells 
encounter environmental stresses such as nutrient starvation, autophagy can be activated 
and protects cells by preventing them from undergoing apoptosis. Through autophagy, 
starving cells degrade cytoplasmic material to generate both nutrients and energy [85]. 
Consistent with this, during nutrient starvation, inhibition of autophagy promotes apoptosis 
[164]. 
b. Autophagy is induced by hypoxia 
Hypoxia in tumours results from inadequate tumour vasculature and is associated with a 
more malignant phenotype, higher predisposition for metastasis, and poor prognosis. 
Hypoxic stress selects for cells that are resistant to apoptosis as well as poses a major barrier 
to chemotherapy and radiotherapy. 
White and colleagues first showed that autophagy is induced specifically in the hypoxic 
core of tumours, where it promotes survival [163]. Further studies have unveiled the 
molecular connections between hypoxia and the activation of autophagy. For example, it 
has been reported that when oxygen concentration falls below 5% hypoxia inducible 
factor 1 (HIF1) is activated and this transcription factor activates key autophagy inducers 
(BNIP3), which in turn activate the key autophagy complex formed by PI3K III [165,166]. 
Further mechanistic studies have revealed that induction of BNIP3 and BNIP3L in 
hypoxic cells disrupts the Becn1-Bcl-2 complex, thereby releasing Becn1 to induce 
autophagy [167].  
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The role of autophagy as a key mediator of survival of hypoxic cells is emerging so that the 
exact mechanisms underlying this phenotype remain unclear. Because chronic hypoxia 
leads to major metabolic perturbations in tumour tissues, one can postulate that by recycling 
basic cellular components, autophagy helps stressed cells cope with the increased metabolic 
demand [168]. However, further studies are needed to validate this hypothesis.  
c. Autophagy is induced in metastatic cells 
Epithelial cells critically depend on cell adhesion to extracellular matrix (ECM) for proper 
growth and survival. Upon detachment of cells from the ECM, cells undergo anoikis, a type 
of apoptotic cell death that serves the homeostatic function of killing cells that have lost 
contact with the basement membrane [68]. It has been shown that autophagy is induced in 
oncogene-transformed cells following matrix detachment [169]. Similarly, in three 
dimensional (3D) epithelial cell culture models, autophagy is significantly increased in the 
detached luminal cells. Furthermore, when autophagy is inhibited accelerated luminal 
clearance occurs [158,169]. Altogether, these results suggest that autophagy is fundamental 
in anoikis resistance, a process exploited by tumour cells to survive after detachment from 
the primary site, as well as while migrating to distant metastatic sites [170].  
Debnath and colleagues have shown that detachment induces autophagy in both 
nontumourigenic epithelial cell lines and in primary epithelial cells. Autophagy inhibition 
through siRNA for ATG genes inhibits detachment-induced autophagy and increases 
apoptosis. Remarkably, even when apoptosis is inhibited matrix-detached cells still exhibit 
autophagy. Moreover, inhibition of autophagy in MCF-10 acini enhances luminal apoptosis 
during morphogenesis and fails to elicit long-term luminal filling [171]. Altogether, these 
results indicate that autophagy promotes epithelial cell survival during anoikis, including in 
detached cells harbouring antiapoptotic lesions. 
14. Current therapeutic advances 
In addition to inactivation of proliferative and prosurvival oncogenic pathways, current 
anticancer strategies deal with reactivation of cancer death cell signalling routes in order to 
induce tumour regression. The most promising cancer therapies that specifically target 
apoptosis, necrosis/necroptosis and autophagy are described in the following section. 
14.1. Extrinsic apoptotic pathway 
TRAIL: This member of the TNF family stimulates the extrinsic apoptotic pathway in a wide 
variety of cancers upon binding to death receptors, while having no effect on normal cells. 
Therefore, the use of recombinant TRAIL or agonistic TRAIL-receptor antibodies constitutes 
a novel therapeutic strategy [172]. TRAIL has been found to bind five receptors in human 
cells: TRAIL-R1, TRAIL-R2, TRAIL-R3 (DcR1), TRAIL-R4 (DcR2) and the soluble receptor 
osteoprogeterin. However, DcR1 and DcR2 are unable to transduce a death signal and are 
considered “decoy receptors”. Ashkenazi and colleagues have proposed that the specificity 
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of TRAIL for cancer cells is due to the fact that normal cells express more frequently these 
decoy receptors [173]. Moreover, TRAIL only weakly induces the prosurvival NFkB 
pathway [78]. Unfortunately, many primary tumour cell lines have shown resistance to 
TRAIL [174]. It has been shown that in preclinical studies, the combination of recombinant 
human TRAIL (rhTRAIL, AMG951, Dulanermin) or agonistic antibodies with irradiation, 
several chemotherapeutic agents, Akt or proteosome inhibitors induced cell death in 
tumours resistant to TRAIL [175-177]. Therefore, the efficacy of rhTRAIL or anti-TRAIL-R1/2 
antibodies is being examined in different phase I and phase II clinical trails alone or in 
combination with other chemotherapeutic agents [172,178,179]. 
Fas activating compounds: Fas, also called CD95 or APO-1 is a member of the TNF family of 
death receptors involved in the extrinsic apoptotic pathway. Fas plays an important role in 
regulation of the immune system. This receptor belongs to a subgroup within the TNFR 
family which includes TNFR1, DR3, TRAIL-R4 and TRAIL-R5 [180]. Fas has been recently 
implicated in the activation of RIP1, resulting in necroptosis when caspase-8 is inactive 
[181,182]. In addition, Tschopp and colleagues have demonstrated that Fas can activate 
other signalling pathways involved in proliferation or differentiation [109]. Fas agonists, 
such as highly aggregated FasL or anti-Fas antibodies are not suitable for cancer therapy 
owing to their profound liver toxicity. However, weaker Fas agonists may be useful. In this 
respect, APO010 is undergoing clinical trials for solid tumours [109].  
14.2. Intrinsic apoptotic pathway 
Bcl-s inhibitors/BH3 mimetics: Many efforts in cancer therapeutics are directed towards 
inhibition of antiapoptotic Bcl-2 like proteins. The first class of drugs being developed was 
antisense nucleotides. Oblimersen has been tested in clinical trials in different types of 
cancers. Even though some clinical trials shows efficacy of oblimersen combined with 
chemotherapy in treating melanoma [183], other studies show that this Bcl-2 inhibitor does 
not confer significant benefit to cancer patients [178]. Small molecule Bcl-2 inhibitors are also 
called “BH3 mimetics”, as they imitate the function of BH3-only proteins: Gossypol (AT-
101) binds Bcl-2, Bcl-XL and MCl-1, inhibiting their binding to Bax and Bak. In combination 
with other chemotherapeutic agents it promotes apoptosis in preclinical studies and has 
shown efficacy in at least one clinical trial [178]. Obotoclax is a pan Bcl-2 inhibitor that 
induces apoptosis in leukemia cells. However, recent studies have shown that its activity is 
partially mediated by autophagy [184,185]. Therefore, caution should be taken when using 
these kinds of drugs. ABT-737 and its orally available derivative, ABT-263 (navitoclax), have 
shown promising results in preclinical studies. They bind Bcl-2, Bcl-XL and Bcl-w [186], but 
mildly inhibit Mcl-1 [187] or A1 [101]. ABT-727 synergizes with standard chemotherapeutic 
agents, radiation and tyrosine kinase inhibitors in cancer cells and is effective as a single 
agent promoting tumour regression in mice. ABT-263 is currently in phase I and II clinical 
trails as a single agent [78,188]. However, its use is limited because it causes 
trombocytophenia owing to Bcl-XL inhibition [189]. A new BH-3 mimetic agent, GDC-0199 
has been developed and entered clinical trails for lymphomas [101]. 
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IAP inhibitors and Smac mimetics: Moreover, the role of IAPs in regulating apoptosis and/or 
necroptosis has led to the development of small molecules that antagonize IAP, or mimic the 
function of Smac/DIABLO. In fact, IAPs have been found to be overexpressed in many 
cancers and to be associated with poor prognosis and chemoresistance [102], making them 
putative targets for cancer therapeutics. Smac mimetics can sensitize chemoresistant cancer 
cells to cisplatin, doxorubicin or TRAIL [190], either as single agents or in combination with 
other drugs [109]. Therefore, some of these agents (AT-406, LCL-161, HGS-1029, TL32711, 
GDC-0917) [73] have recently entered clinical trials [191] for the treatment of solid tumours 
and lymphomas [192]. However, the potential of Smac mimetics as antitumour agents has 
been questioned, since the inhibition of cIAP1 and cIAP2 can stabilize IKK and activate the 
proinflammatory NFkB pathway [102].  
Other IAP-targeted therapies such as XIAP and survivin antisense oligonucleotides have 
been developed [102]. Antisense oligonucleotides against survivin synergize with etoposide 
in non small lung cancer cells [117]. LY2181308 is a second generation antisense 
oligonucleotide being evaluated in clinical trials. In addition, a small molecule inhibitor of 
survivin, YM155, has shown potency in preclinical models and has entered phase II clinical 
trails [110].  
14.3. DNA damage and cell cycle 
p53 inhibitors: Since p53 is frequently mutated in tumours, therapeutic approaches have been 
made to restore p53 function. Since p53 is targeted to degradation through interaction with 
mdm2, some drugs such as RITA, Nutlin-3 or HLI198 have been designed to disrupt p53-
mdm2 interaction. These compounds bind to the p53 binding site on mdm2 or inhibit mdm2 
ubiquitin ligase activity. This approach is valid in cancers with wild type p53, such as 
haematological malignancies [56]. A second approach is to rescue wild-type 53 function in 
p53-mutated tumours. PRIMA-1 restores sequence-specific DNA binding and active 
conformation of mutant p53 proteins. PRIMA-1 can synergize with conventional 
chemotherapeutic drugs and inhibit tumour growth in mice with no apparent toxicity and 
has recently entered clinical trials [78]. 
Chk1/2 inhibitors: The concept of “synthetic lethality” coined by Kaelin, by which two 
molecular lesions combine to have a lethal effect on the cell, although neither of them is 
harmful individually, has recently gained interest [193,194]. In this context, Chk inhibitors 
may have a therapeutic potential in p53-mutated tumours. UCN-01, the first Chk inhibitor 
evaluated in humans, has limited clinical value due to its toxicity. Other Chk inhibitors 
functioning as checkpoint abrogators that are being evaluated in clinical trials are: AZD7762, 
LY26303618, CBT501, PF-00477736, SCH 900776, XL844, and the wee-1 inhibitor MK-1775 
[195,196]. 
PARP inhibitors: Other example of synthetic lethality is BRCA mutant breast cancer. BRCA1 
and BRCA2 play a role in homologous recombination, an important repair pathway for 
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DNA double strand breaks. The current hypothesis is that since PARP is involved in repairs 
in DNA single strands breaks, inhibition of PARP leads to accumulation of single strand 
unrepaired breaks and becomes synthetically lethal in BRCA-mutated cancers [197]. Several 
PARP inhibitors are being evaluated in clinical trials: AG014699, AZD2281 (olaparib), 
ABT888 (veliparib), BSI-201 (iniparib), INO-1001, GP121016, CEP-9722 and MKI4827 
[197,198]. PARP inhibitors may be useful in tumours bearing other types of genomic or 
functional defects in DNA damage response pathways. 
14.4. Necroptosis 
cFLIP: This antiapoptotic regulator is expressed as long (c-FLIPL) short (c-FLIPS) or c-FLIPR 
variants in human cells. In the absence of cFLIP, the ripoptosome triggers apoptotic cell 
death. On the contrary, expression of cFLIPL, which binds caspase-8, neutralizes its ability to 
engage the apoptotic machinery, but inhibits necroptosis by preventing RIP1-RIP3 
association. On the other hand, c-FLIPS, although is able to bind caspase-8, does not form an 
active heteromer and necroptosis can develop [78,199]. Increased expression of c-FLIP has 
been found in several human cancers and is associated with poor prognosis [102]. 
Downregulation of FLIP seems to be a promising therapeutic strategy. Research efforts are 
being focused on the development of small interference RNA (siRNA) targeted against c-
FLIP. In addition, several antitumour agents can downregulate c-FLIP at the transcriptional 
or posttranscriptional level [200].  
14.5. Autophagy 
a. Autophagy as a protective mechanism  
A large series of anticancer drugs (both clinically approved and experimental) are able to 
induce a significant accumulation of autophagosomes in tumour cells both in vitro and in 
vivo [201]. For many years, it was thought that these therapies may kill tumours through 
autophagy and this massive vacuolization of the cytoplasm has been considered a 
manifestation of autophagic cell death. According to this notion, autophagy would 
represent another mechanism of cell death and the inhibition of autophagy would protect 
the cell from dying. However, this perspective is nowadays rather discredited, as the 
majority of the literature has reported that specific inhibition of autophagy (through siRNA) 
contributes to cell death during cancer treatment [202-204]. Besides, it is now well accepted 
that acquired resistant to chemotherapeutic drugs is, in part, due to the adaptive prosurvival 
response conferred by autophagy. Also, several studies have shown that inhibition of 
autophagy by pharmacological inhibitors such as Bafilomycin A1, cloroquine, or 3-
methyladenine can enhance and accelerate cytotoxic cancer therapy in several tumours [205-
207]. In particular, some reports show that chloroquine as a single agent is sufficient to 
promote tumour regression in transplanted cancer models [208,209]. Moreover, chloroquine is 
a well-tolerated nontoxic drug that has entered a clinical trail as monotherapy for pancreatic 
cancer treatment [78]. This clearly indicates that the induction of autophagy represents an 
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attempt of the cells to cope with the stress induced by cytotoxic drugs and suggests that the 
inhibition of the autophagic process might be beneficial in cancer treatment. 
b. Autophagy as a death mechanism  
Although there is robust evidence indicating that autophagy has a protective role in cancer 
therapeutics, in certain cancer treatments, autophagy can kill cells by inducing autophagic 
cell death. For example, Abe and colleagues have demonstrated that harmol, a β-carboline 
alkaloid, triggered autophagic cell death in human lung carcinoma A549 cells without 
activation of caspase-3, caspase-8, or caspase-9 or PARP cleavage. Autophagy, but not 
apoptosis, was detected by electron microscopy in these cancer cells. Furthermore, 
pretreatment of A549 cells with the autophagy inhibitor 3-methyladenine or siRNA-
mediated knockdown of LC3 suppressed harmol-induced cell death [210]. Another study 
shows that L929 fibrosarcoma cells die in a caspase-independent manner involving 
autophagy and that ATG genes are required for this cell death process [211]. In this model, 
caspase inhibition induces the selective autophagic degradation of catalase, a major ROS 
scavenger, and the resulting ROS accumulation promotes autophagic cell death [212].  
14.6. What determines if autophagy is cytoprotective or cytotoxic? 
Autophagy is a process that allows cells to escape death or paradoxically leads to cell death. 
It is not yet understood what factors determine whether autophagy is cytoprotective or 
cytotoxic. It has been suggested that autophagy induced under pathological conditions 
functions as an adaptive cell response, allowing the cell to survive bioenergetic stress. 
However, autophagy is a process that destroys cellular content and organelles. In this 
way, it has been suggested that deregulated, excessive or persistent autophagy may lead 
to autophagic cell death. That is, the destruction of proteins and organelles may pass a 
threshold, leading to cell death. However, the point at which autophagy becomes 
autophagic cell death remains unclear. In this perspective, the dissection of the transition 
from autophagy to autophagic cell death and the cross-talking between apoptosis and 
autophagy may help to understand this process, leading to more efficacious treatments in 
cancer. In contrast, a different study has reported that when cells are subjected to 
prolonged growth factor deprivation or shortage of glucose and oxygen they can lose the 
majority of their mass via autophagy. However, when these cells are placed in optimal 
culture conditions, they are able to fully recover [163,213]. This result suggests that cell 
death via autophagy may not be simply a matter of crossing a quantitative threshold of 
self-digestion. 
14.7. Interplay among apoptosis, necrosis/necroptosis and autophagy 
Cell death process in vivo involves a complex interaction among apoptosis, 
necrosis/necroptosis and autophagy [78]. In some situations, a specific stimulus triggers 
only one mechanism, but in other cases, the same stimulus can evoke more than one cell 
demise machinery. Therefore, several mechanisms can coexist within a cell, but only one 
will predominate over the others. The decision to undergo apoptosis, necrosis/necroptosis or 
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autophagy depends on various factors: energy/ATP availability, extent of the stress and the 
damage and presence of inhibitors of particular pathways (e. g. caspases inhibitors) [214]. 
ATP depletion activates autophagy, but if autophagy fails to maintain energy levels, 
necrosis/necroptosis results [215]. Apoptosis is usually triggered with sufficient ATP levels 
to trigger caspases. If the damage is severe necrosis prevails over apoptosis [216,217]. Hence, 
apoptosis is the first choice in most circumstances and necroptosis is triggered only as a 
backup alternative to guarantee that cell death takes place. However, in some cases (e.g. 
viral infection) TNF-mediated necroptosis predominate [218]. Apoptosis can inhibit 
autophagy through Bcl-2-mediated sequestration [155,156] or caspase-dependent cleavage 
of Beclin 1 [219,220,220], and conversely, autophagy can inhibit apoptosis by caspase-8 
degradation [221]. 
15. Concluding remarks 
Programmed cell death mechanisms are intricate and usually interconnected processes. 
Evasion of cell death is a common feature of cancer cells leading to chemoresistance. 
Apoptosis, necrosis/necroptosis and autophagy are the main explored pathways that had 
gained interest among cancer biologists, as means to develop novel cancer therapeutics. 
Deeping our knowledge on the nexus between cell death and cancer will enable us to 
predict in a more refined manner the carcinogenic process and therefore, pave the way for a 
personalized approach to the disease. 
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